|
1
|
Hu J, Qian GS and Bai CX: Lung Cancer
Study Group of Chinese Thoracic S and Chinese Alliance Against Lung
Cancer Expert Group: Chinese consensus on early diagnosis of
primary lung cancer (2014 version). Cancer. 121:(Suppl 17).
S3157–S3164. 2015. View Article : Google Scholar
|
|
2
|
Ho JC, Tam TC and Lam SK: Salvage therapy
beyond targeted therapy in lung adenocarcinoma. Semin Respir Crit
Care Med. 34:837–844. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
West H, Harpole D and Travis W: Histologic
considerations for individualized systemic therapy approaches for
the management of non-small cell lung cancer. Chest. 136:1112–1118.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ang YL, Tan HL and Soo RA: Best practice
in the treatment of advanced squamous cell lung cancer. Ther Adv
Respir Dis. 9:224–235. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ravandi F, Estey E, Jones D, Faderl S,
O'Brien S, Fiorentino J, Pierce S, Blamble D, Estrov Z, Wierda W,
et al: Effective treatment of acute promyelocytic leukemia with
all-trans-retinoic acid, arsenic trioxide, and gemtuzumab
ozogamicin. J Clin Oncol. 27:504–510. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rojewski MT, Körper S and Schrezenmeier H:
Arsenic trioxide therapy in acute promyelocytic leukemia and
beyond: From bench to bedside. Leuk Lymphoma. 45:2387–2401. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Park JW, Choi YJ, Jang MA, Baek SH, Lim
JH, Passaniti T and Kwon TK: Arsenic trioxide induces G2/M growth
arrest and apoptosis after caspase-3 activation and bcl-2
phosphorylation in promonocytic U937 cells. Biochem Biophys Res
Commun. 286:726–734. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Evens AM, Tallman MS and Gartenhaus RB:
The potential of arsenic trioxide in the treatment of malignant
disease: Past, present, and future. Leuk Res. 28:891–900. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zheng CY, Lam SK, Li YY and Ho JC: Arsenic
trioxide-induced cytotoxicity in small cell lung cancer via altered
redox homeostasis and mitochondrial integrity. Int J Oncol.
46:1067–1078. 2015.PubMed/NCBI
|
|
10
|
Lam SK, Mak JC, Zheng CY, Li YY, Kwong YL
and Ho JC: Downregulation of thymidylate synthase with arsenic
trioxide in lung adenocarcinoma. Int J Oncol. 44:2093–2102.
2014.PubMed/NCBI
|
|
11
|
Lam SK, Li YY, Zheng CY, Leung LL and Ho
JC: E2F1 downregulation by arsenic trioxide in lung adenocarcinoma.
Int J Oncol. 45:2033–2043. 2014.PubMed/NCBI
|
|
12
|
Euhus DM, Hudd C, LaRegina MC and Johnson
FE: Tumor measurement in the nude mouse. J Surg Oncol. 31:229–234.
1986. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ardalan B, Subbarayan PR, Ramos Y,
Gonzalez M, Fernandez A, Mezentsev D, Reis I, Duncan R, Podolsky L,
Lee K, et al: A phase I study of 5-fluorouracil/leucovorin and
arsenic trioxide for patients with refractory/relapsed colorectal
carcinoma. Clin Cancer Res. 16:3019–3027. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Au WY, Kumana CR, Lee HK, Lin SY, Liu H,
Yeung DY, Lau JS and Kwong YL: Oral arsenic trioxide-based
maintenance regimens for first complete remission of acute
promyelocytic leukemia: A 10-year follow-up study. Blood.
118:6535–6543. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nakagawa Y, Akao Y, Morikawa H, Hirata I,
Katsu K, Naoe T, Ohishi N and Yagi K: Arsenic trioxide-induced
apoptosis through oxidative stress in cells of colon cancer cell
lines. Life Sci. 70:2253–2269. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Elmore S: Apoptosis: A review of
programmed cell death. Toxicol Pathol. 35:495–516. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Han YH, Kim SZ, Kim SH and Park WH:
Arsenic trioxide inhibits the growth of Calu-6 cells via inducing a
G2 arrest of the cell cycle and apoptosis accompanied with the
depletion of GSH. Cancer Lett. 270:40–55. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Silke J, Kratina T, Ekert PG, Pakusch M
and Vaux DL: Unlike Diablo/smac, Grim promotes global
ubiquitination and specific degradation of X chromosome-linked
inhibitor of apoptosis (XIAP) and neither cause apoptosis. J Biol
Chem. 279:4313–4321. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Seite P, Hillion J, d'Agay MF, Gaulard P,
Cazals D, Badoux F, Berger R and Larsen CJ: BCL2 gene activation
and protein expression in follicular lymphoma: A report on 64
cases. Leukemia. 7:410–417. 1993.PubMed/NCBI
|
|
20
|
Chao DT and Korsmeyer SJ: BCL-2 family:
Regulators of cell death. Annu Rev Immunol. 16:395–419. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Satoh MS and Lindahl T: Role of poly
(ADP-ribose) formation in DNA repair. Nature. 356:356–358. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Han YH, Kim SZ, Kim SH and Park WH:
Arsenic trioxide inhibits growth of As4.1 juxtaglomerular cells via
cell cycle arrest and caspase-independent apoptosis. Am J Physiol
Renal Physiol. 293:F511–F520. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kim HR, Kim EJ, Yang SH, Jeong ET, Park C,
Kim SJ, Youn MJ, So HS and Park R: Combination treatment with
arsenic trioxide and sulindac augments their apoptotic potential in
lung cancer cells through activation of caspase cascade and
mitochondrial dysfunction. Int J Oncol. 28:1401–1408.
2006.PubMed/NCBI
|
|
24
|
Ghobrial IM, Witzig TE and Adjei AA:
Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin.
55:178–194. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Huang CL, Liu D, Nakano J, Yokomise H,
Ueno M, Kadota K and Wada H: E2F1 overexpression correlates with
thymidylate synthase and survivin gene expressions and tumor
proliferation in non small-cell lung cancer. Clin Cancer Res.
13:6938–6946. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Rustum YM, Harstrick A, Cao S, Vanhoefer
U, Yin MB, Wilke H and Seeber S: Thymidylate synthase inhibitors in
cancer therapy: Direct and indirect inhibitors. J Clin Oncol.
15:389–400. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Boukovinas I, Papadaki C, Mendez P, Taron
M, Mavroudis D, Koutsopoulos A, Sanchez-Ronco M, Sanchez JJ,
Trypaki M, Staphopoulos E, et al: Tumor BRCA1, RRM1 and RRM2 mRNA
expression levels and clinical response to first-line gemcitabine
plus docetaxel in non-small-cell lung cancer patients. PLoS One.
3:e36952008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Rosell R, Danenberg KD, Alberola V, Bepler
G, Sanchez JJ, Camps C, Provencio M, Isla D, Taron M, Diz P, et al:
Ribonucleotide reductase messenger RNA expression and survival in
gemcitabine/cisplatin-treated advanced non-small cell lung cancer
patients. Clin Cancer Res. 10:1318–1325. 2004. View Article : Google Scholar : PubMed/NCBI
|
